Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyNeighborhood Health Plan Empaveli Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Empaveli (pegcetacoplan) subcutaneous for C3G and IC-MPGN - Clinical prior authorization

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical prior authorization policy for subcutaneous Empaveli (pegcetacoplan) for members (Medicaid, Commercial, Medicare) with biopsy‑confirmed Complement 3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN), including initial and renewal requirements and dosing guidance.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyEmpaveli (pegcetacoplan) subcutaneous for C3G and IC-MPGN - Clinical prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewDec 9, 2025
    Next Review DateDec 9, 2025
    Key ActionObtain prior authorization; initial approvals valid for 6 months and may be renewed every 6 months when renewal criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    initial prior authorization length
    2,160 mgmax units per 7 days
    >=12minimum covered age
    >=30eGFR threshold
    UPCR>=1proteinuria threshold

    Coverage Criteria for Empaveli (pegcetacoplan)

    Initial Therapy

    Coverage is provided when ALL of the following are met:

    Initial approval criteria: Member has biopsy-confirmed diagnosis of C3G OR IC-MPGN; member is >= 12 years of age; drug is prescribed by or in consultation with a nephrologist; UPCR >= 1 g/g OR proteinuria >= 1.0 g/day; eGFR >= 30 mL/min/1.73 m2; member is receiving a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months prior to initiation and will continue during treatment OR has intolerance/contraindication to RAS inhibitors; member will NOT be using Empaveli in combination with Fabhalta (iptacopan); member does NOT have any FDA-labeled contraindications to Empaveli.see individual nodes

    All conditions required

    Continuation / Renewal Therapy

    Coverage will be provided when ALL of the following are met:

    Renewal criteria: Member has diagnosis of C3G or IC-MPGN; drug is prescribed by or in consultation with a nephrologist; member has had improvement or stabilization as shown by EITHER decrease from baseline UPCR OR decrease from baseline in proteinuria; member is receiving stable maximally tolerated RAS inhibitor therapy or has intolerance/contraindication to RAS inhibitors; documentation that member's eGFR remains >=30 mL/min/1.73 m2; member will NOT be using Empaveli with Fabhalta (iptacopan); member does NOT have any FDA-labeled contraindications to Empaveli.see individual nodes

    All conditions required for renewal

    Use of Empaveli (pegcetacoplan) in combination with Fabhalta (iptacopan) is not permitted. This prohibition applies to both initial therapy requests and renewal requests and is a required condition for coverage under the policy.

    Empaveli is considered not medically necessary and will not meet coverage criteria when any of the following apply: UPCR < 1 g/g (equivalently, proteinuria < 1.0 g/day), eGFR < 30 mL/min/1.73 m2, or when the diagnosis of C3G or IC-MPGN is not confirmed by kidney biopsy. These thresholds apply to both initial requests and renewals and must be documented in the medical record.

    Billing & Coding

    HCPCS CodesHCPCS
    J7799Non-chemotherapeutic drugs, other than inhalation drugs, administered through DME
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use Only)
    J3490Unclassified drugs
    NDCNDC
    73606-0010-xxEmpaveli 1,080 mg/20 mL solution in single-dose vials for subcutaneous infusion
    Covered Diagnosis Codes (ICD-10)ICD-10Covered
    D59.5Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]
    N00.AAcute nephritic syndrome with C3 glomerulonephritis
    N00.5Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
    N00.6Acute nephritic syndrome with dense deposit disease
    N01.ARapidly progressive nephritic syndrome with C3 glomerulonephritis
    N01.5Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
    N01.6Rapidly progressive nephritic syndrome with dense deposit disease
    N02.ARecurrent and persistent hematuria with C3 glomerulonephritis
    N02.5Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis
    N02.6Recurrent and persistent hematuria with dense deposit disease
    1–10 of 25
    1/3
    inv-08: UPCR threshold
    UPCR threshold for initial coverageUrine protein-to-creatinine ratio (UPCR) >= 1 g/g
    Role in criteriaRequired for initial approval (member must have UPCR >=1 g/g OR proteinuria >=1.0 g/day)
    Renewal implicationRenewal may be based on decrease from baseline UPCR as evidence of improvement or stabilization
    inv-09: Proteinuria
    Proteinuria threshold (g/day)Proteinuria >= 1.0 g/day
    Equivalence to UPCRMeets coverage when UPCR >=1 g/g OR proteinuria >=1.0 g/day

    Provider Actions, Documentation & Denial Triggers

    Prior Authorization

    Prior authorization required; 6‑month approvals

    Prior authorization is required for Empaveli; initial approvals are valid for 6 months and may be renewed every 6 months thereafter when renewal criteria are met.

    Step Therapy

    Medicare step therapy exemption for prior recipients

    Medicare members who have previously received Empaveli within the past 365 days are not subject to step therapy requirements and are exempt from step therapy.

    Documentation Required

    Required clinical documentation for authorization

    Background

    Empaveli (pegcetacoplan) is a targeted C3 complement inhibitor indicated for treatment of adults and pediatric patients aged 12 years and older with biopsy‑confirmed Complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC‑MPGN) to reduce proteinuria. Clinical evidence supporting coverage includes a randomized trial demonstrating reductions in urine protein-to-creatinine ratio (UPCR) and higher rates of ≥50% UPCR reduction versus placebo with stable eGFR. Common adverse events reported include injection/infusion site reactions, fever, respiratory infections, cough, and nausea.

    Definitions

    inv-16: UPCR
    DefinitionUrine protein-to-creatinine ratio (UPCR): primary efficacy endpoint in trials and a coverage threshold used by the policy
    Clinical useUsed to assess response: reduction from baseline UPCR supports renewal
    Coverage ruleUPCR >=1 g/g is required for initial coverage (alternative to proteinuria >=1.0 g/day)
    inv-17: C3G
    DefinitionComplement 3 glomerulopathy (C3G): diagnosis must be confirmed by kidney biopsy for coverage
    Role in criteriaBiopsy-confirmed C3G is required for initial approval or renewal documentation
    Age requirement
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyEmpaveli (pegcetacoplan) subcutaneous for C3G and IC-MPGN - Clinical prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 1, 2026
    Last ReviewDec 9, 2025
    Next Review DateDec 9, 2025
    Key ActionObtain prior authorization; initial approvals valid for 6 months and may be renewed every 6 months when renewal criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for Empaveli (pegcetacoplan)Billing & CodingProvider Actions, Documentation & Denial TriggersBackgroundDefinitions
    Use in renewalRenewal may be supported by decrease from baseline in proteinuria
    inv-10: eGFR
    eGFR thresholdEstimated glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m2
    Required at initiationMember's eGFR must be >=30 mL/min/1.73 m2 for initial approval
    Required for renewalDocumentation that member's eGFR remains >=30 mL/min/1.73 m2 for renewal

    Submit documentation confirming biopsy‑proven C3G or IC‑MPGN, member age, and that the drug is prescribed by or in consultation with a nephrologist; include baseline and current UPCR or proteinuria, baseline and current eGFR, evidence of maximally tolerated RAS inhibitor therapy (or documentation of intolerance/contraindication), and dosing information based on body weight.

    • Kidney biopsy report confirming C3G or IC‑MPGN
    • Member age (≥ 12 years for initial approval)
    • Prescriber specialty: nephrologist or nephrology consultation documentation
    • Baseline and current UPCR or proteinuria values
    • Baseline and current eGFR (must remain ≥30 mL/min/1.73 m2 for renewal)
    • Documentation of stable, maximally tolerated RAS inhibitor therapy for ≥3 months prior to initiation, or reason for intolerance/contraindication
    • Dosing information (dose and schedule based on body weight)
    Denial Risk

    Triggers that may lead to denial of request

    Requests that do not meet all initial or renewal coverage criteria may be denied.

    • No kidney biopsy confirming C3G or IC‑MPGN
    • Member age under 12 years at initiation
    • UPCR < 1 g/g or proteinuria < 1.0 g/day
    • eGFR < 30 mL/min/1.73 m2
    • Not receiving, or lacking documentation of, maximally tolerated RAS inhibitor therapy without documented intolerance/contraindication
    • Use of Empaveli in combination with Fabhalta (iptacopan)
    • Presence of any FDA‑labeled contraindication to Empaveli
    Member must be >=12 years of age to receive coverage for C3G indication
    inv-18: IC-MPGN
    DefinitionImmune-complex membranoproliferative glomerulonephritis (IC-MPGN): diagnosis must be confirmed by kidney biopsy for coverage
    Role in criteriaBiopsy-confirmed IC-MPGN is required for initial approval or renewal documentation
    Coverage equivalenceIC-MPGN is an alternative covered diagnosis to C3G for Empaveli therapy